Interleukin 12 Receptor (IL12R) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Interleukin 12 Receptor (IL12R) – Pipeline Review, H2 2016’, provides in depth analysis on Interleukin 12 Receptor (IL12R) targeted pipeline therapeutics.

The report provides comprehensive information on the Interleukin 12 Receptor (IL12R) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 12 Receptor (IL12R) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Interleukin 12 Receptor (IL12R)

The report reviews Interleukin 12 Receptor (IL12R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Interleukin 12 Receptor (IL12R) targeted therapeutics and enlists all their major and minor projects

The report assesses Interleukin 12 Receptor (IL12R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Interleukin 12 Receptor (IL12R) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Interleukin 12 Receptor (IL12R)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Interleukin 12 Receptor (IL12R) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Eli Lilly and Company

Mallinckrodt Plc

Merck KGaA

Neumedicines Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Interleukin 12 Receptor (IL12R) Overview 6

Therapeutics Development 7

Interleukin 12 Receptor (IL12R) - Products under Development by Stage of Development 7

Interleukin 12 Receptor (IL12R) - Products under Development by Therapy Area 8

Interleukin 12 Receptor (IL12R) - Products under Development by Indication 9

Interleukin 12 Receptor (IL12R) - Pipeline Products Glance 10

Late Stage Products 10

Early Stage Products 11

Interleukin 12 Receptor (IL12R) - Products under Development by Companies 12

Interleukin 12 Receptor (IL12R) - Therapeutics Assessment 14

Assessment by Monotherapy/Combination Products 14

Assessment by Mechanism of Action 15

Assessment by Route of Administration 17

Assessment by Molecule Type 18

Interleukin 12 Receptor (IL12R) - Companies Involved in Therapeutics Development 20

Eli Lilly and Company 20

Mallinckrodt Plc 21

Merck KGaA 22

Neumedicines Inc 23

Interleukin 12 Receptor (IL12R) - Drug Profiles 24

Cellular Immunotherapy to Activate Interleukin-12 for Skin Cancer - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

edodekin alfa SR - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

LY-3232094 - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

M-9241 - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

NMIL-121 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

Interleukin 12 Receptor (IL12R) - Dormant Projects 32

Interleukin 12 Receptor (IL12R) - Discontinued Products 33

Interleukin 12 Receptor (IL12R) - Featured News & Press Releases 34

Mar 02, 2015: Department of Defense Supports Neumedicines With Groundbreaking Grant for Surgical Site Infection Therapy 34

Apr 28, 2014: Phase I Clinical Study of Neumedicines' Interleukin-12 as a Treatment for Wound Healing and Infections Recommended for Funding by the U.S. Department of Defense 34

Apr 18, 2014: Neumedicines Publishes Clinical Data Demonstrating Safety and Hematopoietic and Immune Effects of HemaMax (rHuIL-12), a Radiation Medical Countermeasure 35

Apr 15, 2014: Neumedicines Announces Publication of Phase II-Equivalent Data Demonstrating the Survival Effect of HemaMax (rHuIL-12), a Radiation Medical Countermeasure 36

Jan 09, 2014: Neumedicines to Feature HemaMax Study Results in Presentation at Biotech Showcase Conference 36

Dec 13, 2013: Neumedicines Presents HemaMax Clinical Data at the ASH Conference 37

Jun 10, 2013: Neumedicines Receives $8.3m Award From BARDA For Continued Development Of HemaMax As Countermeasure To Acute Radiation Exposure 38

May 14, 2013: Neumedicines Receives BARDA Notification Of Intent To Exercise Contract Option To Continue Development Of HemaMax As Radiation Medical Countermeasure 38

Jan 25, 2013: Neumedicines Presents Data On HemaMax At BARDA And NIAID Sponsored Symposium 39

Jul 23, 2012: TherapyX Partners with Neumedicines 40

May 05, 2012: Neumedicines's HemaMax Demonstrates Unprecedented Survivability After Lethal Dose Of Radiation In Mice And Non-Human Primates 40

Mar 05, 2012: Neumedicines’s HemaMax Demonstrates Positive Preclinical Results After Lethal Dose Of Radiation In Mice And Non-Human Primates 42

Sep 27, 2011: Neumedicines Wins US Federal Government Contract Up To $273m To Fund Late-Stage Development Of HemaMax 43

Jan 31, 2011: Neumedicines Receives Notice Of Allowance For Patent Covering Use Of HemaMax To Treat Chemotherapy-Induced Thrombocytopenia 44

Aug 12, 2010: Neumedicines Receives $2.5 Million From HHS/BARDA After Successful Non-Human Primate Studies to Further Advance HemaMax As a Radiation Countermeasure 44

Appendix 46

Methodology 46

Coverage 46

Secondary Research 46

Primary Research 46

Expert Panel Validation 46

Contact Us 46

Disclaimer 47

List of Tables

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Products under Development by Companies, H2 2016 13

Assessment by Monotherapy/Combination Products, H2 2016 14

Number of Products by Stage and Mechanism of Action, H2 2016 16

Number of Products by Stage and Route of Administration, H2 2016 17

Number of Products by Stage and Molecule Type, H2 2016 19

Pipeline by Eli Lilly and Company, H2 2016 20

Pipeline by Mallinckrodt Plc, H2 2016 21

Pipeline by Merck KGaA, H2 2016 22

Pipeline by Neumedicines Inc, H2 2016 23

Dormant Projects, H2 2016 32

Discontinued Products, H2 2016 33

List of Figures

List of Figures

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Top 10 Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Assessment by Monotherapy/Combination Products, H2 2016 14

Number of Products by Mechanism of Actions, H2 2016 15

Number of Products by Stage and Mechanism of Actions, H2 2016 15

Number of Products by Stage and Routes of Administration, H2 2016 17

Number of Products by Molecule Types, H2 2016 18

Number of Products by Stage and Molecule Type, H2 2016 18

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports

Analytics by GoSquared